Evidence map›Paper›PMID 33614514›Full record

ReviewFrontiers in oncology2021

Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2.

Dristhi Ragoonanan, Sajad J Khazal, Rodrigo Mejia, Linette Ewing, Jean-Bernard Durand, Lara Bashoura, Jean Tayar, Natalie Dailey Garnes, Demetrios Petropoulos, Priti Tewari and 19 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Dristhi RagoonananPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Sajad J KhazalPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Rodrigo MejiaPediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Linette EwingPediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Jean-Bernard DurandDepartment of Cardiology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Lara BashouraDepartment of Pulmonary Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Jean TayarDepartment of Rheumatology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Natalie Dailey GarnesDepartment of Infectious Disease, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Demetrios PetropoulosPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Priti TewariPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Micah BhattiDepartment of Pathology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Ali Haider AhmadPediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Jose CortesPediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Shehla RazviPediatric Critical Care Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Katrina McBethDepartment of Pediatric Pulmonary Medicine, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Rita SwinfordDepartment of Pediatric Nephrology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Basirat ShoberuPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Waseem WaseemuddinPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Linda ChiDepartment of Neuroradiology, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Jonathan B GillDepartment of Pediatric Oncology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Wafik ZakyDepartment of Pediatric Oncology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Najat DawDepartment of Pediatric Oncology, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Cristina GutierrezDepartment of Critical Care Medicine, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Welela TereffeUniversity of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Partow KebriaeiStem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Katayoun RezvaniStem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Elizabeth J ShpallStem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Richard E ChamplinStem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.
Kris M MahadeoPediatric Stem Cell Transplantation and Cellular Therapy, CARTOX Program, University of Texas at MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We describe 2 diagnostically challenging cases of SARS-CoV-2 and Multi-Inflammatory Syndrome-Adult (MIS-A), in patients with a history of acute lymphoblastic leukemia following cellular therapy administration and review evolving characterization of both the natural course of SARS-CoV-2 infection and toxicities experienced in younger cancer immunotherapy patients. Vigilant monitoring for unique presentations and epidemiologic surveillance to promptly detect changes in incidence of either condition may be warranted.

Indexed as

cancer immunotherapyCOVID-19MIS-AMIS-CSARS-CoV-2

Identifiers

PMID33614514
PMCPMC7891040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.